Changmao Biochemical Engineering Company Limited provided earnings guidance for the year 2022. The board of directors of the Company announced the shareholders of the Company and potential investors that having assessed the currently available information, the Group is likely to record a consolidated net profit attributable to the equity holders of the Company 2022 of an amount ranging between RMB 70 million to RMB 90 million as compared to consolidated net loss attributable to the equity holders of the Company of RMB 49.2 million for 2021, before taking into account the Demolition Gain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.455 HKD | 0.00% | +1.11% | -22.88% |
26/03 | Changmao Biochemical Engineering Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
29/02 | Changmao Biochemical Engineering to Swing to Loss in 2023 | MT |
1st Jan change | Capi. | |
---|---|---|
-22.88% | 3.09Cr | |
+6.34% | 11TCr | |
-10.78% | 5.96TCr | |
+61.90% | 4.54TCr | |
+14.54% | 3.81TCr | |
+1.03% | 3.13TCr | |
+9.32% | 1.97TCr | |
+10.83% | 1.65TCr | |
+7.90% | 1.38TCr | |
-5.22% | 1.3TCr |
- Stock Market
- Equities
- 954 Stock
- News Changmao Biochemical Engineering Company Limited
- Changmao Biochemical Engineering Company Limited Provides Earnings Guidance for the Year 2022